Drugs / BCMA-CD19 cCAR T cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06787989 | Aug 2024 → Aug 2026 overdue | — | iCell Gene Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT05474885 | Apr 2022 → Apr 2025 | systemic lupus erythematosus | iCell Gene Therapeutics | Unknown | No outcome recorded |
| Phase 1 | NCT04162353 | Jul 2019 → Jul 2026 overdue | plasma cell myeloma | iCell Gene Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCMA-CD19 cCAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05474885 ↗ |
| Action | Deplete | “The use of two different targets intends to increase coverage and eradicate cancerous cells before resistance develops in surviving cancer cells that have undergone selective...” NCT04162353 ↗ |
| Modality | Cell therapy | “BCMA-CD19 cCAR T cells transduced with a lentiviral vector to express two distinct units of BCMA and CD19 CARs on a T cell” NCT04162353 ↗ |
| Route | Intravenous | “by IV injection” NCT04162353 ↗ |